Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

被引：0
|
作者：
Hiroshi Yokouchi
Koichi Yamazaki
Ichiro Kinoshita
Jun Konishi
Hajime Asahina
Noriaki Sukoh
Masao Harada
Kenji Akie
Shigeaki Ogura
Takashi Ishida
Mitsuru Munakata
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura
机构：
[1] Hokkaido University School of Medicine,First Department of Medicine
[2] Hokkaido University Graduate School of Medicine,Department of Medical Oncology
[3] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine
[4] Sapporo City General Hospital,Department of Respiratory Disease
[5] Fukushima Medical University,Department of Pulmonary Medicine
[6] KKR Sapporo Medical Center,Department of Medical Oncology
[7] Hokkaido Lung Cancer Clinical Research Group,undefined
来源：
BMC Cancer | / 7卷
关键词：
Overall Survival; Epidermal Growth Factor Receptor; Bone Metastasis; Gefitinib; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib
    Schuler, Martin
    Fischer, Juergen R.
    Grohe, Christian
    Guetz, Sylvia
    Thomas, Michael
    Kimmich, Martin
    Schneider, Claus-Peter
    Laack, Eckart
    Maerten, Angela
    ONCOLOGIST, 2014, 19 (10): : 1100 - 1109
  • [22] Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Fujita, Shiro
    Kunimasa, Kei
    Nanjo, Shigeki
    Otsuka, Kyoko
    Kaji, Reiko
    Tomii, Keisuke
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Hayashi, Hidetoshi
    Morita, Satoshi
    Ishida, Tadashi
    LUNG CANCER, 2011, 74 (02) : 268 - 273
  • [23] Gefitinib or Erlotinib in the Treatment of Advanced Non-small Cell Lung Cancer
    Shao, Yu-Yun
    Lin, Chia-Chi
    Yang, Chih-Hsin
    DISCOVERY MEDICINE, 2010, 9 (49) : 538 - 545
  • [24] Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective
    Jiang, Haiyi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (03) : 137 - 150
  • [25] Analysis of the response and toxicity to gefitinib of non-small cell lung cancer
    Konishi, J
    Yamazaki, K
    Kinoshita, I
    Isobe, H
    Ogura, S
    Sekine, S
    Ishida, T
    Takashima, R
    Nakadate, M
    Nishikawa, S
    Hattori, T
    Asahina, H
    Imura, M
    Kikuchi, E
    Kikuchi, J
    Shinagawa, N
    Yokouchi, H
    Munakata, M
    Dosaka-Akita, H
    Nishimura, M
    ANTICANCER RESEARCH, 2005, 25 (1B) : 435 - 441
  • [26] Predictors of the response to gefitinib in refractory non-small cell lung cancer
    Kim, KS
    Jeong, JY
    Kim, YC
    Na, KJ
    Kim, YH
    Ahn, SJ
    Baek, SM
    Park, CS
    Park, CM
    Kim, YI
    Lim, SC
    Park, KO
    CLINICAL CANCER RESEARCH, 2005, 11 (06) : 2244 - 2251
  • [27] Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
    Shimomura, Iwao
    Tada, Yuji
    Miura, Gen
    Suzuki, Toshio
    Matsumura, Takuma
    Tsushima, Kenji
    Terada, Jiro
    Kurimoto, Ryota
    Sakaida, Emiko
    Sekine, Ikuo
    Takiguchi, Yuichi
    Yamamoto, Shuichi
    Tatsumi, Koichiro
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2013, 2013
  • [28] Gefitinib for Non-Small Cell Lung Cancer Patients with Liver Cirrhosis
    Kim, Young Hak
    Mio, Tadashi
    Mishima, Michiaki
    INTERNAL MEDICINE, 2009, 48 (18) : 1677 - 1679
  • [29] Gefitinib treatment for carcinomatous meningitis in Non-Small Cell Lung Cancer
    Chouahnia, K.
    Brechot, J. -M.
    Des-Guetz, G.
    Saintigny, P.
    Morere, J. -F
    Breau, J. -L.
    REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (02) : 149 - 151
  • [30] Predictors of clinical response of non-small cell cancer to gefitinib - Reply
    Kris, MG
    Kay, AC
    Ochs, JJ
    Wolf, MK
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (13): : 1563 - 1564
12345